



FINANCIAL STATEMENTS

YEAR ENDED JUNE 30, 2012

**WASHINGTON VACCINE ASSOCIATION
TABLE OF CONTENTS
YEAR ENDED JUNE 30, 2012**

INDEPENDENT AUDITORS' REPORT	1
FINANCIAL STATEMENTS	
STATEMENT OF FINANCIAL POSITION	2
STATEMENT OF ACTIVITIES	3
STATEMENT OF CASH FLOWS	4
NOTES TO FINANCIAL STATEMENTS	5



CliftonLarsonAllen

CliftonLarsonAllen LLP
www.cliftonlarsonallen.com

INDEPENDENT AUDITORS' REPORT

Board of Directors
Washington Vaccine Association
Seattle, Washington

We have audited the accompanying statement of financial position of Washington Vaccine Association (a nonprofit organization) as of June 30, 2012, and the related statements of activities and cash flows for the year then ended. These financial statements are the responsibility of the organization's management. Our responsibility is to express an opinion on these financial statements based on our audit.

We conducted our audit in accordance with auditing standards generally accepted in the United States of America. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audit provides a reasonable basis for our opinion.

In our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of Washington Vaccine Association as of June 30, 2012, and the results of its operations and its cash flows for the year then ended, in conformity with accounting principles generally accepted in the United States of America.

CliftonLarsonAllen LLP

CliftonLarsonAllen LLP

Bellevue, Washington
September 7, 2012

**WASHINGTON VACCINE ASSOCIATION
STATEMENT OF FINANCIAL POSITION
JUNE 30, 2012**

ASSETS

CURRENT ASSETS

Cash and Cash Equivalents	\$ 7,372,452
Investments	20,042,762
Member Assessments Receivable	<u>1,183,381</u>
Total Current Assets	<u><u>\$ 28,598,595</u></u>

LIABILITIES AND NET ASSETS

CURRENT LIABILITIES

Accounts Payable	\$ 135,562
Vaccine Fees Payable to Washington Department of Health	<u>3,239,060</u>
Total Current Liabilities	3,374,622

**ASSESSMENTS COLLECTED IN EXCESS OF VACCINE FUNDING
AND ADMINISTRATIVE ACTIVITIES**

25,223,973

NET ASSETS - UNRESTRICTED

0

Total Liabilities and Net Assets	<u><u>\$ 28,598,595</u></u>
----------------------------------	-----------------------------

See accompanying Notes to Financial Statements.

**WASHINGTON VACCINE ASSOCIATION
STATEMENT OF ACTIVITIES
YEAR ENDED JUNE 30, 2012**

	Administrative Activities	Vaccine Funding Activities	Total
CHANGE IN UNRESTRICTED NET ASSETS			
Assessment Activities:			
Assessments Collected	(\$8,035,601)	\$44,713,821	\$36,678,220
Vaccine Replenishments	0	(32,400,989)	(32,400,989)
Net Assessments Activity	(8,035,601)	12,312,832	4,277,231
Revenue:			
Interest Income	45,792	0	45,792
Unrealized Gain on Investments	5,174	0	5,174
Total Revenue	50,966	0	50,966
Expenses:			
Public Information	2,939	0	2,939
Administrative	507,494	0	507,494
Vaccine Development	79,950	0	79,950
Office	62,347	0	62,347
Other	23,335	0	23,335
Total Expenses	676,065	0	676,065
Total Change in Unrestricted Net Assets	(8,660,700)	12,312,832	3,652,132
ASSESSMENTS COLLECTED IN EXCESS OF VACCINE FUNDING AND ADMINISTRATIVE ACTIVITIES	8,660,700	(12,312,832)	(3,652,132)
CHANGE IN NET ASSETS	0	0	0
Net Assets - Beginning of Year	0	0	0
NET ASSETS - END OF YEAR	\$0	\$0	\$0

See accompanying Notes to Financial Statements.

**WASHINGTON VACCINE ASSOCIATION
STATEMENT OF CASH FLOWS
YEAR ENDED JUNE 30, 2012**

CASH FLOWS FROM OPERATING ACTIVITIES

Assessments Collected	\$ 40,420,536
Interest Received	45,792
Cash Remittances to Washington Department of Health for Vaccines	(30,834,866)
Administrative Expenses Paid	(647,846)
Net Cash Provided by Operating Activities	8,983,616

CASH FLOWS FROM INVESTING ACTIVITIES

Purchase of Investments	(20,037,588)
-------------------------	--------------

NET DECREASE IN CASH

(11,053,972)

Cash and Cash Equivalents - Beginning of Year

18,426,424

CASH AND CASH EQUIVALENTS - END OF YEAR

\$ 7,372,452

**RECONCILIATION OF CHANGE IN NET ASSETS TO NET CASH
PROVIDED BY OPERATING ACTIVITIES**

Change in Net Assets	\$0
Adjustments to Reconcile Change in Net Assets to Net Cash Provided by Operating Activities:	
Unrealized Gain on Investments	(5,174)
Decrease in Assets:	
Member Assessments Receivable	3,742,316
Increase in Liabilities:	
Accounts Payable	28,465
Vaccine Fees Payable to Washington Department of Health	1,566,123
Assessments Collected in Excess of Vaccine Funding and Administrative Activities	3,651,886
Net Cash Provided by Operating Activities	\$ 8,983,616

See accompanying Notes to Financial Statements.

**WASHINGTON VACCINE ASSOCIATION
NOTES TO FINANCIAL STATEMENTS
JUNE 30, 2012**

NOTE 1 NATURE OF ORGANIZATION

Organization and Operations

Since 1990, Washington State has maintained a Universal Childhood Vaccine Program, providing vaccines to all children under age 19. Together with federal funding, Washington's program has advanced the widely recognized benefits of universal childhood vaccination. Faced with a scheduled end to state funding in 2010, the Washington State legislature established the universal vaccine purchase account to be able to continue providing state-supplied vaccines to privately-insured children. This legislation was adopted after a year of study by and with broad support from the Washington health care community.

Washington Vaccine Association (the Association) is a special purpose nonprofit corporation formed on April 1, 2010 to support the state government in developing and administering a new method for collecting funds to support the Universal Childhood Vaccine Program. The Washington legislature created the Association through the Washington Vaccine Association Act, now codified in Chapter 70.290 RCW.

The Association's members are comprised of all health insurance carriers issuing or renewing health benefit plans in Washington State, and all third-party administrators (TPAs) conducting business on behalf of residents of Washington State or Washington health care providers.

The Association's primary purpose is to raise funds through mandatory assessments paid by its members. Payments are made to the State of Washington Department of Health (DOH) for the purchase of vaccines. The vaccines are to be administered to children in the State of Washington who are under the age of 19 and who are not eligible for free vaccines under one or more federal programs.

The Association is operated under a Plan of Operation adopted by the board of directors as required by Washington State House Bill 2SHB 2551. The Association's governance documents are available at the Association's website: www.WAvaccine.org.

Termination of the Association

The Association board may, on or after June 30, 2015, vote to recommend termination of the Association if it finds that the original intent of its formation and operation has not been achieved. The Association board must provide notice of the recommendation to the relevant policy and fiscal committees of the Washington State legislature within 30 days of the vote being taken by the Association board. If the legislature has not acted by the last day of legislative session to reject the board's recommendation, the board may vote to permanently dissolve the Association.

In the event of a voluntary or involuntary dissolution of the Association, funds remaining in the universal purchase vaccine account created in RCW 43.70.720 that were collected under 2SHB 2551 must be returned to members in proportion to their previous year's contribution, from any balance remaining following the repayment of any prepayments for start-up funding not previously recouped by such member.

**WASHINGTON VACCINE ASSOCIATION
NOTES TO FINANCIAL STATEMENTS
JUNE 30, 2012**

NOTE 2 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Accounting

The financial statements of the Association have been prepared in accordance with the provisions of accounting standards generally accepted in the United States of America. Under those standards, net assets and revenues, expenses, gains and losses are classified based on the existence or absence of donor-imposed restrictions. The Association's net assets do not contain restrictions as of June 30, 2012.

Concentration of Risk

Financial instruments that subject the Association to concentrations of credit risk consist of cash deposits. The Association places its cash deposits with high quality financial institutions. Deposits exceed federally insured limits as of June 30, 2012.

Cash and Cash Equivalents

For the purposes of the statement of cash flows, all highly liquid investments available for use with an initial maturity of three months or less are considered to be cash equivalents.

Investments

Investments are reported at fair value. Fair value is the price that would be received to sell an asset in an orderly transaction between market participants at the measurement date. See Note 3 for discussion of fair value measurements. Purchases and sales are recorded on a trade-date basis. Interest income is recorded on an accrual basis. Dividends are recorded on the ex-dividend date. Net appreciation includes the Association's gains and losses on investments bought and sold as well as held during the year.

Accounts Receivable

The Association charges interest on late payment of assessments at a monthly rate of 1.5 percent. Interest is added to the assessment for payments received after the due date of the assessment.

Dosage Based Assessments

Funds collected from health insurers and TPAs of health plans in the state of Washington (including administrative revenue and reserve portion discussed below) are determined using a Dosage Based Assessment methodology. At each administration of vaccines to a non-federally-eligible child in the state of Washington, the provider's office charges for and generates a claim for administrative services and also generates an item, resembling a claim form, on which the per-vaccine assessment is reported to the respective payer. The per-vaccine assessment amounts are established by the Association periodically. The payer pays the provider for the administration claim, and also pays the assessment amount to the Association, in a manner similar to payment of a claim for the cost of vaccines. The Association collects these assessments and remits payments to the State of Washington Treasurer to pay its allocated share of vaccine costs each time a vaccine replenishment order for the state's Universal Childhood Vaccine Program is due. The cost for each vaccine is negotiated by the Center for Communicable Diseases. The DOH invoices the Association for vaccine purchases.

**WASHINGTON VACCINE ASSOCIATION
NOTES TO FINANCIAL STATEMENTS
JUNE 30, 2012**

NOTE 2 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

Revenue Recognition

The Association collects member assessments that are remitted to the DOH for purchase of vaccines. In addition, the Plan of Operation allows the Association to retain sufficient funds to cover its administrative costs, net of investment income. Expense is recognized for the administrative costs of operating the Association. The replenishment of vaccines and collection of vaccine assessments are similar to agency transactions. Although these transactions are not considered revenue or expense of the Association, they are included in the statement of activities as vaccine replenishments to reflect the gross amount of collections and replenishments.

Remittance to Universal Purchase Account

The Plan of Operation requires the Association to periodically remit its assessment receipts, less the Association's administrative costs and any reserves set by the board or the executive director, to the credit of the universal vaccine purchase account (UVPA) established pursuant to RCW 43.70.720. Funds transferred to the UVPA are to be delivered on a just-in-time basis, in order to support the assessment collection process and to enable the Association to gain as much interest income as reasonably possible through its collection process to help offset its costs of administration. The DOH or its designee has access privileges to be able to directly observe the balances in the Association's accounts, and the Association is required to promptly respond to any inquiry of the DOH concerning the availability and timely transfer of funds, enabling the DOH to make payment of the Association's share under the statute for vaccine purchases made by the State of Washington.

Assessments Collected in Excess of Vaccine Funding and Administrative Costs

The Association has collected assessments in excess of amounts required to be paid to the DOH through the end of the accounting period for childhood vaccine funding and administrative costs. The Association is a limited purpose entity whose funds are dedicated solely to the specific purposes discussed above. These excess assessment collections which may accumulate from time to time will be applied to (i) future vaccine funding obligations of the Association, and (ii) reasonable and necessary operating costs of the Association. The Association maintains a level of excess collections (reserves) to be able to meet DOH needs for funding timely. As of June 30, 2012, assessments collected in excess of vaccine funding and administrative activities totaled \$25,223,973.

Income Taxes

The Association follows Financial Accounting Standards Board (FASB) *Accounting Standards Codification* (ASC) Topic 740, *Income Taxes* (Topic 740). Topic 740 clarifies the accounting for uncertainty in income taxes.

The Association operates as a tax-exempt organization created by Washington State statute and an affiliate of a governmental unit. In order to obtain 501(c)(3) status and to determine whether filing of an annual federal information return (Form 990) is required, the Association prepared and submitted Form 1023 to the Internal Revenue Service in June 2012. Management evaluated the Association's tax positions and concluded that the Association had taken no uncertain tax positions that require adjustments to the financial statements to comply with the provisions of this guidance.

**WASHINGTON VACCINE ASSOCIATION
NOTES TO FINANCIAL STATEMENTS
JUNE 30, 2012**

NOTE 2 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

Income Taxes (Continued)

Based upon its evaluation, the Association has concluded that it is operating in compliance within its tax-exempt status and that there are no matters that would create taxable income. The Association's 2009, 2010, and 2011 tax years are open for examination by the IRS should that status be challenged in the future.

Estimates and Assumptions

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

Subsequent Events

The board of directors and management have evaluated subsequent events through September 7, 2012, the date the financial statements were available to be issued.

NOTE 3 INVESTMENTS AND FAIR VALUE OF FINANCIAL INSTRUMENTS

The Association follows FASB ASC 820-10, *Fair Value Measurements* (FASB ASC 820-10). FASB ASC 820-10 defines fair value, establishes a framework for measuring fair value and expands disclosures about financial instruments. In addition, FASB ASC 820-10 establishes a hierarchy that classifies the inputs used to calculate fair value. Financial instruments measured and reported at fair value are classified and disclosed in one of the following categories:

Level 1 – Inputs to the valuation methodology are unadjusted quoted prices for identical assets or liabilities in active markets that the Association has the ability to access.

Level 2 – Inputs to the valuation methodology include:

- quoted prices for similar assets or liabilities in active markets;
- quoted prices for identical or similar assets or liabilities in inactive markets;
- inputs other than quoted prices that are observable for the asset or liability;
- inputs that are derived principally from or corroborated by observable market data by correlation or other means.

Level 3 – Inputs to the valuation methodology are unobservable and significant to the fair value measurement.

**WASHINGTON VACCINE ASSOCIATION
NOTES TO FINANCIAL STATEMENTS
JUNE 30, 2012**

NOTE 3 INVESTMENTS AND FAIR VALUE OF FINANCIAL INSTRUMENTS (CONTINUED)

In many cases, a valuation technique used to measure fair value includes inputs from multiple levels of the fair value hierarchy. The lowest level of input determines the placement of the entire fair value measurement in the hierarchy.

The Association's significant financial instruments are investments which are measured at fair value on a recurring basis as follows:

Corporate Bonds, Commercial Paper, Government Securities, and US Agencies – Fair value is based a complex process utilized by the broker's pricing service (Clearwater Analytics). Clearwater goes through a complex process to determine a baseline for its pricing algorithm along with prices from other sources. Once the baseline is established, all other prices available for the security are pooled together. Clearwater's pricing algorithm is then run with the pool of securities as inputs and the Clearwater Best Price is produced. Clearwater data sources include sources such as Bloomberg, S&P, and Reuters.

The methods described above may produce a fair value calculation that may not be indicative of net realizable value or reflective of future fair values. Furthermore, while the Association believes its valuation methods are appropriate and consistent with other market participants, the use of different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different fair value measurement at the reporting date.

Assets measured at fair value on a recurring basis are summarized below as of June 30, 2012:

	Level 1	Level 2	Level 3	Total
Corporate Bonds:				
Industrial	\$0	\$2,955,742	\$0	\$2,955,742
Utility	0	794,463	0	794,463
Financial	0	4,967,206	0	4,967,206
Commercial Paper:				
Industrial	0	499,582	0	499,582
Financial	0	499,744	0	499,744
U.S. Government Agency Bonds:				
Federal Home Loan Bank	0	500,203	0	500,203
Freddie Mac	0	1,507,275	0	1,507,275
Freddie Mae	0	508,786	0	508,786
U.S. Treasury Notes	0	2,030,814	0	2,030,814
Total Assets at Fair Value	<u>\$0</u>	<u>\$14,263,815</u>	<u>\$0</u>	<u>14,263,815</u>
Cash and Accrued Interest				
Measured at Cost				<u>5,778,947</u>
Total				<u>\$ 20,042,762</u>

**WASHINGTON VACCINE ASSOCIATION
NOTES TO FINANCIAL STATEMENTS
JUNE 30, 2012**

NOTE 4 REMITTANCE TO THE STATE OF WASHINGTON

Pursuant to the Association's statutory purposes, transfers of \$30,834,866 were made by the Association to the State of Washington's Universal Vaccine Purchase Account during the year ended June 30, 2012.

NOTE 5 CONTINGENCIES

There is an inherent risk that a certain portion of the vaccines purchased by the DOH will not be administered to children, resulting in vaccine shrinkage. If member assessments are insufficient for reimbursement to the DOH for purchases of vaccines, the Association would be liable to the DOH to cover the shortfall.